Cotempla XR-ODT - (8.6, 17.3, 25.9 mg; Tablet, Extended-release, Orally Disintegrating)

Generic Name	Methylphenidate	Innovator	Neos Therapeutics
Dosage	8.6, 17.3, 25.9 mg; Tablet, Extended-release, Orally Disintegrating	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	COTEMPLA XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****	*** / ***	*** **, ****	*******	****	** *** **, ****

Chronology Of Events